How Is Post-Market Surveillance Handled for Medical Device Registration in Indonesia?

Post-market surveillance (PMS) for a medical device registered in Indonesia is the responsibility of the registration holder, supported by its appointed local authorized representative and/or importer, and must be maintained in line with the requirements of the Indonesian Ministry of Health (Kemenkes) and the risk-based registration pathway applicable to the device. Before starting any submission, a company should confirm the target market, the product risk class, the applicable regulatory pathway and its existing documentation base, and then assess its technical file, quality management system evidence, labelling and instructions for use (IFU), local representation arrangements, clinical evidence and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, missing evidence or undefined authorization arrangements do not extend the project timeline.

Key Points

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and only then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Indonesian registration typically affects the technical file, authorized representative, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If the project is driven only by the question of "which documents must be submitted", corrections or rework are likely in the areas of model coverage, evidence-chain consistency, label claims and certificate control.

AIMEILI recommends positioning this question within a unified GHWP member state and multi-country market access strategy: use one reusable core technical file to support localisation across different markets, rather than rebuilding documentation from scratch for each country.

Applicable Scenarios and Core Questions

Companies searching for guidance on Indonesian post-market surveillance for medical device registration are usually not looking for a conceptual explanation. They need to judge whether existing documentation can support an Indonesian submission, whether a local agent or authorized representative is required, why timelines are being extended, and which issues could affect the launch plan. Behind this question are typically several connected matters: product classification, registration pathway, evidence chain, label localisation and post-market maintenance responsibility.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the process for a single country is not sufficient. A more valuable approach is to first prepare the core technical file, quality system evidence, performance verification, clinical evidence and labelling/IFU as a reusable version, and then localise them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the intended use, mechanism of action, use scenario, method and duration of body contact, sterility, whether the device is active, and whether it incorporates software or has IVD characteristics. Only then should the risk class and submission pathway be determined. Once the pathway judgement is wrong, all subsequent translation, notarisation, authorisation, testing and supplementary documentation will move in the wrong direction.

For an Indonesian project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who handles regulatory communication, who manages import and post-market incidents, who triggers changes, and who maintains renewal documentation. If these points are left vague in commercial contracts only, market control can easily be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labelling and IFU, authorisation documents, existing registration certificates, manufacturer's declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. IFU claims, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must all support one another. Regulators focus on whether the device is safe, effective and traceable for its intended use, not on how many documents have been uploaded.

Common Pitfalls

• Treating registration as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.
• Translating NMPA documentation directly and submitting it without restructuring the evidence according to the Indonesian pathway.
• Listing too many models and specifications while test reports, clinical evidence or labelling do not cover them adequately.
• Selecting a local agent purely on the basis of sales cooperation, without defining regulatory responsibility, certificate control and post-market maintenance obligations.
• Inconsistency between labels, IFUs, promotional materials and registration claims, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, so that each country requires repeated preparation and both cost and timelines are inflated.

Company Preparation Checklist

Before launching the project, companies are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission has begun.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English IFU.
• Confirm the responsibilities, fees, certificate control and exit mechanism of the local agent or authorized representative.
• Establish a country-specific gap assessment table identifying what must be re-tested, translated, notarised or supported by additional declarations.

AIMEILI's View

AIMEILI advises companies not to view Indonesian registration as a one-off document submission, but to manage it as an overseas market access programme. For companies preparing to enter multiple countries, building a clear core technical file and evidence matrix first and then converting it to each national requirement is usually faster, more stable and more conducive to subsequent changes and certificate renewals than patching documentation country by country.

From a project management perspective, three things should be controlled early: first, product classification and pathway determination; second, the consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of the local partner. If these three items are unclear, the project may still run into repeated issues during deficiency responses, agent communication and post-market maintenance, even if the documentation appears extensive.

In terms of business impact, early gap assessment and evidence reuse directly affect launch timing, certificate ownership and the cost of entering subsequent markets. Companies that treat post-market surveillance as a contractual obligation of the local distributor rather than a controlled internal process often lose visibility over adverse event reporting, labelling version control and renewal deadlines — an exposure that becomes material when the device is expanded to new models or when the authorized representative is changed.

Frequently Asked Questions

Can domestic (NMPA) documentation be used directly for Indonesian registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as-is. Companies need to adjust the documentation structure, language, labelling, authorisation documents and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

Immediately after the target markets and product list have been confirmed. The earlier the gap assessment is completed, the easier it is to arrange re-testing, translation, label adjustments and agent selection in advance.

Why does the choice of local representative affect registration quality?

The local representative typically participates in registration communication, changes, renewals and post-market incident handling. Unclear responsibilities and authorities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project register that manages the product list, model specifications, registration pathway, document owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This allows documentation gaps to be identified in good time and helps management judge whether the project will affect the launch plan.

For companies that already have registrations in several countries, an evidence reuse matrix should also be established, specifying which documents can serve as core evidence and which must be reissued or supplemented with explanations according to national requirements. Labelling and IFUs, clinical evaluation, risk management, performance verification and quality system certificates in particular must remain version-consistent.

• Confirm the target markets and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Define the local agent and certificate control arrangements.
• Track translation, notarisation, testing and deficiency response status.
• Plan post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the device being filed, or if the manufacturing site, model specifications or IFU version do not align with the test reports, additional clarification may be requested even when a large volume of documentation has been prepared.

Companies should establish an evidence consistency checklist before submission, mapping the product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and IFU version, and quality system certificate item by item. This step appears basic, but it can significantly reduce the probability of deficiency letters, particularly for projects involving simultaneous submissions across several GHWP member states or multiple product families.

Localisation and Authorized Representative Responsibilities

An Indonesian registration project usually involves local agent, authorized representative, importer or registration holder arrangements. Companies need to confirm in advance whether the local partner is responsible only for submitting documents, or also for regulatory communication, certificate maintenance, post-market incident reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labelling, IFUs and authorisation documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localisation conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate, isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Completion of registration does not mean that compliance work has ended. Companies must also maintain certificate validity, change records, distributor authorisations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest substantial effort in obtaining the certificate but neglect post-market maintenance; when a manufacturing site change, model expansion, IFU update or agent replacement subsequently occurs, the certificate can easily become disconnected from actual market sales.

AIMEILI recommends managing this question within an annual international registration plan: define target market priorities first, then build a reusable documentation package and a country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only improved efficiency in a single country, but more importantly the development of a repeatable overseas compliance capability that reduces the cost of rebuilding documentation from zero each time a new market is entered.

Further Reading

• Previous: Common Reasons for Deficiency Letters in Indonesian Medical Device Registration
• Next: When Must a Registration Change Be Filed for Indonesian Medical Device Registration?
• Recommended: How Should Documentation Be Prepared for Medical Device Registration in Malaysia?
• Recommended: How Is Product Classification Determined for Medical Device Registration in Malaysia?
• Recommended: How Should the Technical File Be Organised for Medical Device Registration in Malaysia?
• Recommended: How Should Labelling and IFUs Be Localised for Medical Device Registration in Malaysia?
• Recommended: How Should Clinical Evaluation Documentation Be Prepared for Medical Device Registration in Malaysia?
• Recommended: Can Test Reports Be Reused for Medical Device Registration in Malaysia?
• Back to the FAQ Centre

Content Review and Scope

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Source principles: priority is given to official regulatory authorities, international organisations, standards organisations and publicly available regulatory materials; industry media and project experience are used only as supporting judgement. Compiled with reference to the AIMEILI regulatory practice question bank, the medical device international registration knowledge base and public regulatory information; specific projects should be based on the latest requirements of the target country's regulatory authority and the product's documentation base.

Scope: this article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.

Published: 2026-07-10 15:27 | Updated: 2026-07-10 15:27